Disorders with Complex Genetics Alzheimer’s Disease.

Slides:



Advertisements
Similar presentations
Sporadic AD familial AD etiology environmental factors, genetic predisposition etiology oligomerization of A 42 and initial (diffuse) A 42 deposits subtle.
Advertisements

Alzheimer’s Disease Savidra Lucatero, Vinita Mehrotra, Sabrina Rawlings, Jackie Wheeler, & Matt Zustiak.
Alzheimer’s Disease Stephen S. Flitman, MD Medical Director 21 st Century Neurology a division of Xenoscience, Inc. Phoenix, Arizona.
Etiopathogenesis of Alzheimer's disease
Genetics of longevity 1.Heritability Exceptional longevity (90+) a. appears to be a real category b. what is the basis? -reduced incidence.
This is only for personal educational purposes.
ALZHEIMER’S DISEASE Erin Dancey. Overview Alzheimer’s is the most common cause of dementia in adult life and is associated with the selective damage of.
Disorders with Complex Genetics DCGs. Signs & Symptoms: Memory loss for recent events Progresses into dementia  almost total memory loss Inability to.
Genetic Screening for Alzheimer’s Disease Thorstensen: Genetic Screening for Alzheimer's Disease 1.
ALZHEIMER'S DISEASE (AD)
Neurobiology of Learning and Memory Prof. Anagnostaras Lecture 10: Alzheimer’s Disease and Cognitive Decline in Aging.
CSF tau Is it an informative biomarker of AD pathology Chris Clark Alzheimer’s Disease Center University of Pennsylvania.
The Role of Beta Amyloid proteins in Alzheimer’s Disease What is A.D.?
Amyloid beta protein may initiate a cascade leading to AD pathology.
Alzheimer’s Disease Find group of ~4 students ~ 10 minutes Discuss the following personal family connection to AD (if willing only) observations/experiences.
ALZHEIMER’S AND DOWN’S SYNDROME
Alzheimer’s Disease: Genetics, Pathogenesis, Models, and Experimental Therapeutics.
Aging, Memory and Alzheimer’s Disease Kinga Szigeti, MD, PhD.
Genetics and Dementia – what do relatives want to know? Candy Cooley NHS National Genetic Awareness Lead Genetics and genomics for healthcare
Alzheimer’s Disease By: Ryan Triplett. Alzheimer’s The deterioration of intellectual capabilities, memory, judgment, and personality to the extent that.
Dr. Amr Moustafa Biochemistry Unit Department of Pathology.
Chapter 14 – The Human Genome
Alzheimer's disease Beta amyloid protein and the potential for anti-oxidants drugs.
Genes, Environment- Lifestyle, and Common Diseases Chapter 5.
Standardization of Pedigree Collection. Genetics of Alzheimer’s Disease Alzheimer’s Disease Gene 1 Gene 2 Environmental Factor 1 Environmental Factor.
Dementia syndrome.
Biological Myths of Aging Memory declines drastically with age for all people. IQ declines drastically with age in all people. Learning becomes more difficult.
Progress Report on Alzheimer’s Disease Taking the Next Steps NIA NIH.
Alzheimer Disease By Ashley Wallace. Facts Discovered by Alois Alzheimer in 1907Discovered by Alois Alzheimer in /3 or more of all diagnosed cases.
COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.
VIII. NEURODEGENERATIVE DISEASES. - Are disorders characterized by the cellular degeneration of subsets of neurons that typically are related by function,
Disorders with Complex Genetics. Signs & Symptoms: Memory loss for recent events Progresses into dementia  almost total memory loss Inability to converse,
WHAT DO YOU REMEMBER ABOUT ALZHEIMER’S DEMENTIA?.
Introduction Alzheimer’s disease (AD) is a neurodegenerative disease associated with brain shrinkage and the loss of neurons, particularly cholinergic.
Alzheimer’s Disease -> The Disease of Darkness Varun Doshi.
Diego, Jackie, and Pete 1/27/10 Period 2.  Alzheimer’s Disease is a progressive and fatal brain disease.  Over 5 million people have it.  Early symptoms.
Molecular mechanism for Alzheimer’s disease : searching for the possible therapeutic targets Sungkwon Chung Dept. of Physiology Sungkyunkwan Univ. School.
Dr. Usman Ghani CNS Block.  Pathophysiology of alzheimer’s disease: 5I.
10 signs to early detection 1. Memory loss that affects daily life 2. Challenges in planning or solving problems 3. Difficulty completing projects at.
1 Genes, Environment- Lifestyle, and Common Diseases Chapter 5.
Genes, Environment, and Common Diseases Chapter 5 Mosby items and derived items © 2010, 2006 by Mosby, Inc., an affiliate of Elsevier Inc.
National Institute on Aging
Alzheimer’s Disease Jeff, Luke, and Vivek 1 February 2010 Period 6-07.
Alzheimer’s Disease Gavin Mast, Musa Abdus-Samad, Arash Rezaeian, Sarah Rocha PHM142 Fall 2015 Instructor: Dr. Jeffrey Henderson.
Epidemiology of Alzheimer’s Disease
ALZHEIMER’S WHAT IS IT – WHAT TO DO ABOUT IT. VIDEO
Under the supervision of miklós jászberényi
Neurobiology of Dementia Majid Barekatain, M.D., Associate Professor of Psychiatry Neuropsychiatrist Isfahan University of Medical Sciences Ordibehesht.
1 Dr.Wael Mansy, Ph.D. Department of Clinical Pharmacy College of Pharmacy / King Saud University.
Genetic aspects of Alzheimer disease Karolina Pesz, Błażej Misiak, Maria M. Sasiadek Department of Genetics Wroclaw Medical University, Poland.
HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part B – AD and brain systems NUCLEAR MEDICINE GRAND ROUNDS.
Alzheimer’s Disease (AD)
Trends in Biomedical Science Theories of Alzheimer’s Disease.
DEGENERATIVE DISEASES is a disease in which the function or structure of the affected tissues or organs will progressively deteriorate over time, whether.
Alzheimer Disease (Senile Dementia) Characterized by progressive memory loss, is increasingly common in developed countries as populations include more.
Alzheimer’s Disease and Cholesterol
Alzheimer’s Disease (AD)
Title: Alzheimer’s disease and the social
Alzheimer’s Disease Putting the pieces together
Alzheimer’s Disease Dr. Usman Ghani CNS Block.
Alzheimer’s Disease CNS Block.
Alzheimer’s Disease.
Alzheimer’s Disease 1 in 9 people in the US aged 65 and older
65 year-old female with Alzheimer’s disease
Amnesia Syndromes Lecture 21.
Progress Report on Alzheimer’s Disease
Disorders with Complex Genetics
Probing the Biology of Alzheimer's Disease in Mice
Drugs for Degenerative Diseases of the Nervous System
Alzheimer’s Disease Dr. Usman Ghani Neuropsychiatry Block.
Presentation transcript:

Disorders with Complex Genetics Alzheimer’s Disease

Signs & Symptoms: Memory loss for recent events Progresses into dementia  almost total memory loss Inability to converse, loss of language ability Affective/personality disturbance (fatuous, hostile) Death from opportunistic infections, etc. Confirmation of Diagnosis: Neuronal (amyloid,  amyloid, A  amyloid) plaques Neurofibrillary tangles Brain Atrophy

Neuronal Plaques in Alzheimer’s Disease From

Neurofibrillary Tangles in Alzheimer’s Disease From

Plaques and neurofibrillary tangles From Department of Pathology, Virginia Commonwealth University

WRONG! Brain Atrophy in AD

Classification: (1) FAD v SAD: Familial AD versus Sporadic AD No complete consensus Usually FAD = at least 1 first degree relative affected Sometimes 2 second degree relatives (2) Early v Late Onset: Early onset = usually before 65 Early onset correlated with FAD LOAD = late onset AD

Breakthrough: (1) Down’s Syndrome Have AD brain pathology in later life Usually, do NOT have AD symptoms (2) Pedigrees with dominant-like transmission: Studied these first Concentrated on chromosome 21

Alzheimer’s Disease, Type 1: Several mutations in APP gene on chromosome 21 Most common = Val717Iso Produce abnormal beta amyloid fragment 15%-20% of early onset, familial AD Autosomal dominant

Alzheimer’s Disease, Type 3: Mutations (> 130) in the presenilin1 gene on chromosome 14 Most mutations lead to amino acid substitution Overproduction of the beta amyloid fragment 30% - 70% of early onset, familial AD Autosomal dominant

Alzheimer’s Disease, Type 4: Mutations in the presenilin2 gene on chromosome 1 2 alleles: Asn141Iso and Met239Val Overproduction of the beta amyloid fragment < 5% of early onset, familial AD (only a few families world wide) Autosomal dominant

Alzheimer’s Disease, Type 2: Epsilon 4 (  4, AKA E4) allele of the Apolipoprotein E (ApoE) gene on chromosome 19 confers risk Epsilon 2 (  2, AKA E2) allele of the Apolipoprotein E gene on chromosome 19 confers protection Mechanism unclear; ApoE is a very low density lipoprotein that transports cholesterol Most cases are late onset, familial Susceptibility Locus

Prevalence of APOE genotypes in Alzheimer’s disease (AD) and controls. Genotype:ControlsAD E2/E21.3%0% E2/E312.5%3.4% E2/E44.9%4.3% E3/E359.9%38.2% E3/E420.7%41.2% E4/E40.7%12.9% Jarvik G, Larson EB, Goddard K, Schellenberg GD, Wijsman EM (1996) Influence of apolipoprotein E genotype on the transmission of Alzheimer disease in a community-based sample. Am J Hum Genet 58: genotype

Two Major Hypotheses for AD:  amyloid protein (BAP) v. tau 1.BAPtists : The accumulation of a fragment of the amyloid precursor protein or APP (the amyloid beta 42 residue fragment or Ab-42) leads to the formation of plaques that someone kill neurons. 2.TAUists : Abnormal phosphorylation of tau proteins makes them “sticky,” leading to the break up of microtubules. The resulting loss of axonal transport causes cell death. (Recently a presenilin hypothesis has been proposed by Shen & Kelleher (2007), PNAS, 104: )

Amyloid Hypothesis (it’s the plaques, dummy) 1.The amyloid precursor protein (APP) is broken down by a series of secretases (see next two slides). 2.During this process, a nonsoluble fragment of the APP protein (called A  - 42) accumulates and is deposited outside the cell. 3.The nonsoluble or “sticky” nature of A  -42 helps other protein fragments (including apoE) to gather into plaques. 4.Somehow the plaques (or possible the migration of A  -42 outside the cell) cause neuronal death. 5.PSEN1 & PSEN2 genes  subunits of  secretase.

Amyloid precursor protein (APP) is membrane protein that sits in the membrane and extends outward. It is though to be important for neuronal growth, survival, and repair. From:

Enzymes cut the APP into fragments, the most important of which for AD is called  -amyloid (beta-amyloid) or A . From:

Beta-amyloid is “sticky” so the fragments cling together along with other material outside of the cell, forming the plaques seen in the AD brain. From:

  APP Protein: (1)  -secretase cuts APP protein, giving: (2)  -secretase cuts this residue, giving: or A  40 Fragment Soluble A  42 Fragment Unsoluble, aggregates into plaques  -secretase Pathway: (not drawn to scale)

Tau Hypothesis (it’s the tangles, dummy) 1.Ordinarily, the  (tau) protein is a microtubule-associated protein that acts as a three-dimensional “railroad tie” for the microtubule. The microtubule is responsible for axonal transport. 2.Accumulation of phosphate on the tau proteins cause “paired helical filaments” or PHFs (like two ropes twisted around each other) that accumulate and lead to the neurofibrillary tangles (NFT). PHFs are the main component in NFTs. 3.Impaired axonal transport is the probable cause of cell death. 4.Focus on MAPT gene (microtubule-associated protein tau) 5.Not in favor anymore.

Current theory: Multifactorial, involving several pathways. Protein accumulation:  placques & tangles Inflammation: Unregulated activation of glia Lipid distribution: Lipid membrane site of APP cleavage.

From Sleegers et al. (2010) Trends in Genetics, 26, 84-94, p. 87

Alzheimers Disease

Current gene candidates for AD: Changes too rapidly to keep track of. Go to for latest listhttp://Alzgene.org

Microtubules are like railroad tracks that transport nutrition and other molecules. Tau-proteins act as “ties” that stabilize the structure of the microtubules. In AD, tau proteins become tangled, unstabilizing the structure of the microtubule. Loss of axonal transport results in cell death.

AD: The Great Unknown What is causing the majority of AD cases?

Cases with no known etiology: (theoretical extremes) Mendelian/ Phenocopy Multifactorial/ Threshold CDCV Common disease/ common variant Disease (Genetic) Heterogeneity

Heterogeneity Mendelian/Phenocopy Many rare alleles with high penetrance (“Mendelian” forms of the disorder). Almost no person will get two or more of these AD alleles. Non familial cases due to phenocopies.

Multifactorial Threshold Model Many common alleles with “low” penetrance. Most people will have several risk alleles. Risk alleles are additive (multiplicative). Many additive environmental factors. Genes and environment  liability. Once liability reaches a certain value (i.e., the threshold) a disease process begins.

HGSS: Carey: Figure 6.1

Theoretical major causes of AD:

Mice gratia Human APP gene Human ApoE gene Human Presenilin gene Animal Models

Figure 1. Development of the Transgenic Mouse Model of Alzheimer's Disease. The transgene consists of the human APP gene containing a mutation causing a rare form of early-onset familial Alzheimer's disease (Val717Phe). The transgene, whose expression is driven by the platelet-derived growth factor (PDGF) promoter, is microinjected into mouse eggs and implanted in a pseudopregnant female mouse. After the progeny are screened for the presence of the transgene, they are bred and their offspring are analyzed for pathologic features characteristic of Alzheimer's disease. The brains of the transgenic PDAPP (PDGF promoter expressing amyloid precursor protein) mice have abundant -amyloid deposits (made up of the A peptide), dystrophic neurites, activated glia, and overall decreases in synaptic density. From NEJM Volume 332:

From McGowan, Erikson & Hutton (2006), Trend in Genetics, 22: